Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Argatroban could ...
Groundbreaking results in the RE-LY® trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding Significant reduction ...
(San Diego, Calif., December 7, 2003) – The use of ximelagatran in patients with acute venous thromboembolism is as safe and effective as the current standard treatment of enoxaparin, according to a ...
17th International Congress on Thrombosis, Bologna, 26 October 2002: Important results from the EXPRESS clinical trial for the oral direct thrombin inhibitor (Oral DTI), EXANTA™ (oral ximelagatran and ...
Dabigatran etexilate, the first oral DTI marketed in the United States, is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Dabigatran may ...
New research discovered a unique class of medications that act as blood thinners by inhibiting an enzyme in the genes of tick saliva. The research focused on novel direct thrombin inhibitors from tick ...
DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Savaysa" report has been added to ResearchAndMarkets.com's offering. Savaysa (Edoxaban; Daiichi Sankyo) is a direct oral factor Xa inhibitor indicated for ...
Okay, I'm kidding. But I'd really be impressed! So here goes and good luck! You will have 10 minutes to complete the exam. There will be no "phone-a-friend, "50-50," or "let's-ask-the-audience" ...
The US Food and Drug Administration (FDA) has cleared andexanet alfa (Andexxa) as a reversal agent for the anticoagulant effects of the two most commonly used factor Xa inhibitors in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback